59
Participants
Start Date
March 31, 2010
Primary Completion Date
January 31, 2011
Study Completion Date
January 31, 2011
AIN457
300mg every 4 weeks
AIN457
300mg every 2 weeks
Placebo AIN457
Placebo to AIN457
Novartis Investigative Site, Amman
Novartis Investigative Site, Pátrai
Novartis Investigative Site, Lin-Ko
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Fatih / Istanbul
Novartis Investigative Site, Izmir
Novartis Investigative Site, Grenoble
Novartis Investigative Site, Larissa
Novartis Investigative Site, Ramat Gan
Novartis Investigative Site, Tel Aviv
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Singapore
Novartis Investigative Site, Baltimore
Novartis Investigative Site, Alexandria
Novartis Investigative Site, Hong Kong
Novartis Investigative Site, Sfax
Novartis Investigative Site, Athens
Novartis Investigative Site, Ioannina
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Ankara
Novartis Investigative Site, Ankara
Novartis Investigative Site, Altindag / Ankara
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY